(Rac)-Zevaquenabant

• CAT Number: I045290
• CAS Number: 1610420-28-4
• Molecular Formula: C25H21ClF3N5O2S
• Molecular Weight: 547.98
• Purity: ≥95%
• Synonyms: (NZ)-N-(1-aminoethylidene)-5-(4-chlorophenyl)-4-phenyl-N’-[4-(trifluoromethyl)phenyl]sulfonyl-3,4-dihydropyrazole-2-carboximidamide
• IUPAC Name: N-(1-aminoethylidene)-5-(4-chlorophenyl)-4-phenyl-N'-[4-(trifluoromethyl)phenyl]sulfonyl-3,4-dihydropyrazole-2-carboximidamide
• InChI: InChI=1S/C25H21ClF3N5O2S/c1-16(30)31-24(33-37(35,36)21-13-9-19(10-14-21)25(27,28)29)34-15-22(17-5-3-2-4-6-17)23(32-34)18-7-11-20(26)12-8-18/h2-14,22H,15H2,1H3,(H2,30,31,33)
• InChIKey: NLXIJZHFEOSWPU-UHFFFAOYSA-N
• SMILES: CC(=NC(=NS(=O)(=O)C1=CC=C(C=C1)C(F)(F)F)N2CC(C(=N2)C3=CC=C(C=C3)Cl)C4=CC=CC=C4)N

(Rac)-Zevaquenabant（Cat No.:I045290）is the racemic form of a selective cannabinoid type 1 (CB1) receptor antagonist developed for metabolic and neurological research. By blocking CB1 receptor signaling, it modulates pathways involved in appetite regulation, energy balance, and glucose metabolism. Preclinical and clinical investigations have explored its potential in treating obesity, metabolic syndrome, and related complications. The racemic mixture contains both enantiomers, offering a broader profile for pharmacological evaluation and structure–activity studies. (Rac)-Zevaquenabant serves as a valuable research tool for understanding endocannabinoid system modulation and developing targeted therapies for metabolic and central nervous system disorders.